Publications by authors named "C M Julin"
Clonal hematopoiesis is highly prevalent in elderly patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), and around 20% of BPDCN patients have an associated myeloid malignancy. We present a patient with localized BPDCN and concomitant myelodysplastic syndrome (MDS), previously followed for several years due to clonal cytopenia of unknown significance. Compared targeted next-generation sequencing (NGS) of the skin tumor and sequential bone marrow samples showed shared variants in ASXL1 and TET2 with a de novo NRAS variant in both BPDCN and MDS compared to preceding bone marrow samples.
View Article and Find Full Text PDFArticle Synopsis
- Barriers to Trials
- : The Centre for Epidemic Interventions Research in Norway faced many challenges while trying to conduct randomized trials during the COVID-19 pandemic, leading to the failure of 11 out of 18 proposed trials.
- Legal and Ethical Issues
- : A significant obstacle came from the Norwegian Health Research Act, which requires informed consent from all trial participants, complicating the implementation of these studies.
- Need for Support and Framework
- : The authors concluded that for future pandemic research, it's essential to have both political backing and a legal structure that facilitates conducting such trials effectively.
Susceptibility and infectiousness of SARS-CoV-2 in children versus adults, by variant (wild-type, alpha, delta): A systematic review and meta-analysis of household contact studies.
PLoS One
September 2024
Importance: Understanding the susceptibility and infectiousness of children and adolescents in comparison to adults is important to appreciate their role in the COVID-19 pandemic.
Objective: To determine SARS-CoV-2 susceptibility and infectiousness of children and adolescents with adults as comparator for three variants (wild-type, alpha, delta) in the household setting. We aimed to identify the effects independent of vaccination or prior infection.
Background: Vaccination constitutes an attractive control measure for hepatitis E virus (HEV), a major cause of maternal and perinatal mortality globally. Analysis of pregnant participants in an effectiveness trial of the HEV vaccine HEV239 showed possible HEV239-associated fetal losses. We aimed to conduct a detailed analysis of this safety signal.
View Article and Find Full Text PDFArticle Synopsis
- A study was conducted in Bangladesh to evaluate the safety and effectiveness of a recombinant hepatitis E vaccine (HEV239) in preventing hepatitis E during pregnancy, focusing on pregnant and non-pregnant women aged 16-39.
- The trial involved 67 villages and included over 19,000 participants who received either HEV239 or a control hepatitis B vaccine (Hepa-B), with follow-up for two years post-vaccination.
- Results showed no cases of hepatitis E among pregnant participants in either group, indicating HEV239's mild safety profile was comparable to Hepa-B, with no significant adverse events reported.